Attleboro, Massachusetts Clinical Trials

A listing of Attleboro, Massachusetts clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 14 clinical trials
BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC

This is a single arm Phase Ib/II, open label, safety, pharmacokinetic, pharmacodynamics and efficacy study of ONC201 in combination with Opdivo (Nivolumab) in adult patients with metastatic colorectal cancer, for whom no standard therapy is available. This study will enroll adult patients with metastatic colorectal cancer who progressed after at …

growth factor
neutrophil count
folfiri regimen
Lifespan Cancer Institute: The Miriam and Rhode Island Hospitals
 (9.6 away) Contact site
  • 14 May, 2021
  • 1 location
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in subjects with metastatic pancreatic cancer.

metastatic pancreatic cancer
chemotherapy regimen
Research Site
 (9.6 away) Contact site
  • 24 May, 2021
  • +26 other locations
GEN3013 Trial in Patients With Relapsed Progressive or Refractory B-Cell Lymphoma

The trial is an open-label, multi-center safety trial of epcoritamab GEN3013 (DuoBody-CD3xCD20). The trial consists of two parts: a dose escalation part phase 1, first-in-human (FIH) and an expansion part phase 2a.

combination chemotherapy
refractory b-cell non-hodgkin lymphoma
renal function tests
pet/ct scan
monoclonal protein
Rhode Island Hospital
 (9.6 away) Contact site
  • 24 Feb, 2021
  • +98 other locations
Mifepristone for the Prevention of Relapses of Alcohol Drinking

The goal of this study is to determine if, under stress, alcohol drinking is reduced using mifepristone

Center for Alcohol and Addiction Studies, Brown University
 (8.8 away) Contact site
  • 03 Feb, 2021
  • 1 location
9-ING-41 in Patients With Advanced Cancers

GSK-3 is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3 inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.

growth factor
cytotoxic agents
solid neoplasm
absolute neutrophil count
Rhode Island Hospital
 (9.6 away) Contact site
  • 08 Apr, 2021
  • +15 other locations
Impact of Nicotine Reduction on Adolescent Cigarette Use Alternative Tobacco Use and Harm From Tobacco

Adolescents are an important vulnerable population to consider as the FDA moves toward a nicotine reduction policy. Such a policy, which would mandate a reduction of nicotine in all commercially available cigarettes, has the potential to transform public health and greatly reduce the toll of tobacco-related death and disease. Yet, …

Brown University School of Public Health
 (8.8 away) Contact site
  • 23 Jan, 2021
  • 1 location
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

This clinical study will assess the safety and tolerability of escalating doses of mRNA-2416 alone and in combination with administered fixed doses of durvalumab in participants with relapsed/refractory solid tumor malignancies or lymphoma, as well as the objective response rate (ORR) of mRNA-2416 alone or in combination with durvalumab in …

cancer of the ovary
solid tumour
intraperitoneal chemotherapy
Women & Infants Hospital
 (9.3 away) Contact site
  • 28 Apr, 2021
  • +10 other locations
Study of DF1001 in Patients With Advanced Solid Tumors

DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express …

combination therapy
solid tumor
renal function
Rhode Island Hospital
 (9.6 away) Contact site
  • 14 May, 2021
  • +9 other locations
Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL

This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR0191 in adults with r/r B ALL (Cohort A) and in adults with r/r B-cell NHL (Cohort N).

tyrosine kinase inhibitor
platelet count
pericardial effusion
oxygen saturation
mantle cell lymphoma
Lifespan Cancer Institute at Rhode Island Hospital
 (9.6 away) Contact site
  • 01 May, 2021
  • +10 other locations
Dose Escalation of DF6002 in Patients With Advanced Solid Tumors and Expansion in Selected Indications

This study is a Phase 1/2, open-label, dose-escalation study with a consecutive parallel-group efficacy expansion study, designed to determine the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of DF6002 as monotherapy and in combination with nivolumab.

metastatic urothelial carcinoma
growth factor
lung carcinoma
Rhode Island Hospital
 (9.6 away) Contact site
  • 30 Apr, 2021
  • +6 other locations